UPDATE 1-Regeneron beats fourth-quarter revenue estimates

(Adds Eylea sales in paragraph 2, details on FDA application in paragraph 4)

Feb 2 (Reuters) - Regeneron beat Wall Street estimates for fourth-quarter revenue on Friday as sales of its blockbuster eye drug Eylea met drugmaker's preliminary estimates target. Eylea sales were $1.46 billion, including $123 million from the higher dose version of the drug, in line with the company's previously laid out targets in January.

Total revenue was $3.43 billion, beating analysts' estimates of $3.29 billion, according to LSEG data.

The company also said it has submitted its application to U.S. Food and Drug Administration to expand use of its eczema treatment Dupixent, in patients with a type of lung disease known as chronic obstructive pulmonary disease. (Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)